GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India · Delayed Price · Currency is INR 2,876.50
+5.00 (0.17%)
At close: Sep 23, 2026
BOM:500660 Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 486,449 | 386,822 | 487,432 | 329,173 | 224,319 | 281,714 | |
Market Cap Growth | 4.88% | -20.64% | 48.08% | 46.74% | -20.37% | 15.45% |
Enterprise Value | 459,214 | 366,569 | 466,472 | 313,334 | 211,499 | 270,099 |
Last Close Price | 2871.50 | 2226.84 | 2769.97 | 1839.11 | 1225.40 | 1449.29 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 45.54 | 37.34 | 52.55 | 55.80 | 36.73 | 16.62 |
Forward PE | 40.23 | 34.16 | 49.88 | 44.16 | 35.58 | 42.30 |
PS Ratio | 12.30 | 10.12 | 13.00 | 9.53 | 6.90 | 8.59 |
PB Ratio | 21.45 | 17.06 | 24.98 | 18.52 | 12.88 | 10.58 |
P/TBV Ratio | 21.52 | 17.11 | 25.15 | 18.77 | 13.14 | 10.72 |
P/FCF Ratio | 57.36 | 45.62 | 38.48 | 59.76 | 50.96 | 36.30 |
P/OCF Ratio | 53.85 | 42.82 | 37.79 | 56.56 | 46.33 | 34.75 |
PEG Ratio | - | 2.83 | 3.26 | 6.49 | 1.44 | 2.17 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 11.61 | 9.59 | 12.44 | 9.07 | 6.50 | 8.24 |
EV/EBITDA Ratio | 33.98 | 28.50 | 40.47 | 35.58 | 26.83 | 36.36 |
EV/EBIT Ratio | 35.56 | 29.38 | 41.86 | 37.35 | 28.26 | 38.65 |
EV/FCF Ratio | 54.15 | 43.23 | 36.82 | 56.89 | 48.05 | 34.80 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.03 |
Debt / FCF Ratio | - | 0.04 | 0.01 | 0.03 | 0.04 | 0.03 |
Net Debt / Equity Ratio | -1.20 | -1.20 | -1.27 | -1.03 | -0.94 | -1.06 |
Net Debt / EBITDA Ratio | -2.05 | -2.12 | -2.16 | -2.09 | -2.08 | -3.78 |
Net Debt / FCF Ratio | - | -3.21 | -1.96 | -3.34 | -3.72 | -3.62 |
Asset Turnover | - | 0.91 | 0.98 | 1.00 | 0.82 | 0.85 |
Inventory Turnover | - | 2.93 | 2.81 | 2.75 | 2.62 | 2.55 |
Quick Ratio | - | 1.72 | 1.50 | 1.45 | 1.50 | 1.83 |
Current Ratio | - | 2.03 | 1.79 | 1.84 | 1.88 | 2.18 |
Return on Equity (ROE) | - | 49.11% | 49.75% | 33.53% | 27.59% | 18.39% |
Return on Assets (ROA) | - | 18.50% | 18.17% | 15.24% | 11.75% | 11.28% |
Return on Invested Capital (ROIC) | - | - | - | 2875.95% | - | 299.81% |
Return on Capital Employed (ROCE) | - | 49.00% | 50.60% | 41.30% | 37.40% | 23.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.20% | 2.68% | 1.90% | 1.79% | 2.72% | 6.02% |
FCF Yield | 1.74% | 2.19% | 2.60% | 1.67% | 1.96% | 2.76% |
Dividend Yield | 1.98% | 2.56% | 1.52% | 1.74% | 2.61% | 2.07% |
Payout Ratio | - | 68.92% | 80.79% | 91.80% | 249.80% | 29.89% |
Total Shareholder Return | 1.98% | 2.56% | 1.52% | 1.74% | 2.61% | 2.07% |